As seen in DCAT Value Chain Insights April 2023.
Since the Covid-19 pandemic, patient self-injection has been widely-accepted by the healthcare industry, increasing patient compliance by enabling treatment to continue outside of hospital settings and within outpatient and home environments. While the fast-paced development of sterile injectable devices is driving growth of the global pre-filled syringe market, products such as vaccines and other biologics require specific and unique production processes to optimize both particulate and bioburden control whilst ensuring uncompromised sterility throughout the manufacturing process to maximize patient safety.
Advances in filling technologies, combined with increased development of parenteral drugs and the benefits of patient-centric delivery devices to patients, healthcare professionals, and drug manufacturers compared to traditional vial and syringe drug delivery options, are driving significant growth of new and advanced device formats across the pharmaceutical industry particularly the use of pre-filled syringe (PFS) technologies.
Gloveless, closed systems with robotic handling, filling, and closure processes that provide a high level of sterility and fill accuracy are emerging as key. Partnering with a manufacturer capable of delivering flexible aseptic fill-finish solutions for both small and large-scale production runs across a variety of dosage forms including vials, pre-filled syringes, and cartridges for use in auto-injectors, is essential for delivering products to patients safely and efficiently. Learn about the advanced technologies capable of meeting demand for specialized sterile fill-finish manufacturing and innovative packaging.